Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes

By S. Baldus, C. Heeschen, T. Meinertz, A. Zeiher, J. Eiserich, T. Münzel, M. Simoons, C. Hamm. Circulation, 2003

1,028 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Myeloperoxidase: friend and foe (2005, background): “Further, increased plasma [476] or serum [477] MPO levels in patients with coronary artery disease may serve to identify patients with an increased risk for further cardiovascular events (see ref.”
Biological markers of oxidative stress: Applications to cardiovascular research and practice (2013, background): “…studies, high MPO levels were able to predict increased risk of developing CAD in healthy individuals [74]; cardiovascular events in patients presenting to emergency with chest pain [75]; and increased risk of myocardial infarction and death in patients with acute coronary syndrome [76].”
Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. (2004, background): “Plasma, serum, and leukocyte MPO levels have now been associated with angiographic evidence of coronary artery disease (32); incident risk of myocardial infarction, death, and need for revascularization (33, 34); and enhanced endothelial dysfunction (83).”